Cited by 9Lipid metabolism and disordersLipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Three Novel Mutations in the Apolipoprotein E Gene in a Sample of Individuals with Type 2 Diabetes Mellitus

Open access
Stephens, Jeffrey W, Sozen, M Mert, Whittall, Ros A, Caslake, Muriel J, Bedford, Dorothy, Acharya, Jayshree, Hurel, Steven J, Humphries, Steve E·2005·Clinical Chemistry

Abstract

Background: Apolipoprotein E (apoE) is found in association with triglyceride-rich lipoproteins and is the ligand for the removal of these particles from the plasma. Genetic variations in exon 4 lead to three common gene variants: E2, E3, and E4. Methods: We performed apoE genotyping in 765 individuals with type 2 diabetes. Results: We identified three new variant heteroduplex patterns. Sequencing of these variants revealed three novel mutations that were related to biochemical and clinical characteristics. One mutation produced a frameshift at amino acid position 166, which predicted termination of protein synthesis. This individual had a heteroduplex pattern and sequence of E3E3, which was associated with a change in the plasma isoelectric focusing pattern and a 70% lower plasma concentration of apoE compared with healthy individuals. The other mutations were both single base changes. A CGC>CAC change at amino acid position 150 predicted a substitution of Arg>His. This individual had a heteroduplex pattern and sequence of E2E2, which was not associated with major changes in plasma lipids or apoE concentration. The third individual had a CGC>CCC base change at amino acid position 114, which predicted an Arg>Pro change. This person had a heteroduplex pattern and sequence of E3E3, higher plasma total cholesterol, and moderately decreased plasma apoE. Conclusions: The frequency of new mutations in this sample (1 in 255) is higher than that of a healthy population (1 in 7900). Further screening for common apoE gene variants in individuals at risk for dyslipidemia may reveal abnormal heteroduplex patterns and uncover further mutations in this important lipid-regulating gene.

Integrity signals

Registry

Crossref · 10.1373/clinchem.2004.040121

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • APOE (Ala166fs) showed E2 on isoelectric electrophoresis, while the other allele was E3 and was not associated with hyperlipidemia.

    “APOE (Ala166fs) showed E2 on isoelectric electrophoresis, while the other allele was E3 and was not associated with hyperlipidemia.”
  • A case heterozygous for APOE (Ala166fs) was discovered upon screening diabetic patients in the United Kingdom.

    “In addition, a case heterozygous for APOE (Ala166fs) was discovered upon screening diabetic patients in the United Kingdom43).”
  • A case of an APOE (Arg114Pro) heterozygote was found upon the screening of diabetic patients in the UK who presented with hypercholesterolemia, but this patient's serum lipid levels were normalized by 10 mg of simvastatin.

    “A case of an APOE (Arg114Pro) heterozygote was also found upon the screening of diabetic patients in the UK who presented with hypercholesterolemia, but this patient’s serum lipid levels were normalized by 10 mg of simvastatin43).”
  • Screening of diabetic patients in the United Kingdom found one African patient who was heterozygous for APOE (Arg150His) with the E2/E2 phenotype, but no serum lipid abnormalities.

    “Moreover, screening of diabetic patients in the United Kingdom found one African patient who was heterozygous for APOE (Arg150His) with the E2/E2 phenotype, but no serum lipid abnormalities43).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Stephens, J. W., Sozen, M. M., Whittall, R. A., Caslake, M. J., Bedford, D., Acharya, J., Hurel, S. J., & Humphries, S. E.
Affiliations
  • The Royal Free Hospital (GB)
  • University of Glasgow (GB)
  • University College London (GB)
Venue
Clinical Chemistry
Published
2005-01-01
Volume
51
Issue
1
Pages
119-124
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2044974869
Cited by
9
References
2
Citations by year
2025: 1 · 2018: 1 · 2015: 1 · 2014: 1 · 2012: 2
FWCI
0.44
Type
journal article
Language
en
Open access
Locations
  • Clinical Chemistry (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
apolipoprotein E, type 2 diabetes, novel mutations, frameshift mutation, dyslipidemia, single base changes, total cholesterol
MeSH terms
Apolipoproteins E, Diabetes Mellitus, Type 2, Genotype, Humans, Isoelectric Focusing, Mutation, Phenotype, Sequence Analysis, DNA

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review